You are here

Evidence

Displaying 21 - 30 of 125, sorted by most recent
Contains
Contains
Format: 2025
Greater than or equal to
Robert Redfield, Hanna Umanskiy Ortiz
December 3, 2020

Dr. Robert Redfield, director of the Centers for Disease Control and Prevention (CDC), identifies drug use disorder as the public health crisis of our time.

Wilson Compton, Jason A. Cantone
December 3, 2020

Dr. Wilson Compton, deputy director of the National Institute on Drug Abuse (NIDA), explains what judges need to know about the biology, neurobiology, and chemistry of opioid use disorder.

Christopher Jones, Hanna Umanskiy Ortiz
December 3, 2020

Dr. Christopher Jones, U.S. Public Health Service and Centers for Disease Control and Prevention (CDC), reviews current options (to include methadone, buprenorphine and naltrexone) in Medication-Assisted Treatment (MAT) for those with an opioid use disorder.

Irene M. Keeley
December 3, 2020

In concluding remarks, Judge Irene Keeley (N.D. W.

April 27, 2020

This package of materials was transmitted to Congress on April 27, 2020, concerning amendments to the Federal Rules of Practice and Procedure to become effective on December 1, 2020.

Amendments to the Federal Rules of Practice and Procedure are as follows:

January 7, 2020

In 2019, the residual hearsay exception, Federal Rules of Evidence 807, was amended to fix a number of problems that courts had encountered applying the rule.

October 23, 2019

This package of materials was transmitted to the U.S. Supreme Court on October 23, 2019, concerning amendments to the Federal Rules of Practice and Procedure to become effective on December 1, 2020.

April 25, 2019

This package of materials was transmitted to Congress on April 25, 2019, concerning amendments to the Federal Rules of Practice and Procedure to become effective on December 1, 2019.

Amendments to the Federal Rules of Practice and Procedure are as follows:

Jed S. Rakoff
February 7, 2019

Judge Jed S. Rakoff provides concluding remarks.

Pages

Subscribe to Evidence